MATISSE (NCT05742607) is a single arm phase 2 study, investigating perioperative IPH5201+durva, in addition to neoadjuvant CT in previously untreated pts with resectable stage II to IIIA NSCLC. The ...
Abstract. Zanidatamab zovodotin (ZW49) is an antibody drug conjugate (ADC) comprised of a bispecific anti-HER2 IgG1 antibody (ZW25, zanidatamab) conjugated to a microtubule inhibitor auristatin ...
Abstract. Glioblastoma (GBM) is the most common malignant primary brain tumor. The median survival is less than two years. The mesenchymal (MES) subtype of GBM is particularly associated with ...
Introduction: Sotorasib, a first-in-class KRAS G12C inhibitor, has been FDA-approved for adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who received prior systemic therapies ...
AbstractThe immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions ...
AbstractAlthough genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is ...
Abstract. Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced ...
Abstract. Oncolytic viruses have elucidated the broad anti-tumor properties through selectively destroying tumor cells, promoting tumor antigen release and inducing the activation of immune response.
Abstract. Background: Prostate cancer is the 2nd leading cause of cancer-related deaths among men in the US. CREB binding protein (CBP) and paralog p300 are co-activators of androgen receptor (AR) ...
Cancer Res (2026) 86 (8_Supplement): CT032. While protein-based T cell engagers (TCEs) show promise for hematologic malignancies, challenges remain in safety, efficacy, and durability. ABO2203 ...
AbstractImmune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In this ...
Abstract. 5T4 is an oncofetal antigen with low expression in healthy tissues which is frequently overexpressed in different tumor types. Despite its overexpression in various malignancies and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results